Core Viewpoint - Tongyuan Kang Pharmaceutical-B (02410) has seen its stock rise nearly 5%, currently trading at 13.06 HKD, following the announcement that its investigational drug, TY-9591, has been included in the priority review list by the National Medical Products Administration (NMPA) [1] Company Summary - The investigational drug, TY-9591, is a first-class new drug intended for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 substitutions, along with central nervous system metastases [1] - The inclusion in the priority review list indicates that the review process for TY-9591 will be expedited, potentially allowing for an earlier market launch and providing new treatment options for patients in China [1] Industry Summary - The prioritization of TY-9591 reflects a growing trend in the pharmaceutical industry towards accelerating the approval processes for innovative cancer therapies, particularly those targeting specific genetic mutations [1] - This development may enhance competition in the NSCLC treatment market, as companies strive to bring effective therapies to patients more quickly [1]
港股异动 | 同源康医药-B(02410)午后涨近5% 甲磺酸艾多替尼片获纳入优先审评品种名单